HANS FRYKMAN, MD, PHD
CEO & Founder

Dr. Frykman holds a M.Sc. in chemical engineering from Chalmers University, a Ph.D. in biocatalysis from royal institute of technology, Sweden, and received his M.D. from the Karolinska institute in 2006, with postgraduate medical training at the Karoliska University hospital, the University of Minnesota, the Mayo clinic, Sloan Kettering, and the University of British Columbia. he is a member of the FRCPC and the BC College of Physicians and Surgeons.

MATT FARRER, PHD
CSO & Founder

Prof. Farrer has a Bachelor’s degree in biochemistry from King’s College London, and a Ph.D. in human genetics from St. Mary’s Hospital Medical School, Imperial College London, UK. He did post-doctoral fellowships at the Kennedy-Galton Centre of Medical and Community Genetics, and at Mayo Clinic.

ILARIA GUELLA
CTO

Dr. Guella is a human molecular geneticist whose research interests are primarily directed at understanding how genetic variability acts on neurodegenerative diseases. She received her Ph.D. in molecular and cellular biology from the University of Milan, Italy and then completed a post-doc at the Department of Psychiatry and Human Behavior at the University of California, Irvine. In 2013 Ilaria joined the the Centre for Applied Neurogenetics at the University of British Columbia, where she currently works as a research associate.

DAN EVANS
CIO

Dan received his B.Sc. in Computer and Information Science from Queen's University in 2000. He has 15 years of experience in health informatics, including public health, proteomics, genomics and clinical genetics.

YANWEI XI, PHD
Lab Director

Dr. Xi has a Ph.D. in Developmental Neuroscience from University of Ottawa. He did postdoctoral research in human molecular genetics at the Children’s Hospital of Eastern Ontario, and CCMG training in Clinical Molecular Genetics at the Alberta Children’s Hospital. He is a Diplomate of the American Board of Medical Genetics and Genomics and a Fellow of the American College of Medical Genetics and Genomics.